A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis

Journal of Neurology

Volumn 248, Issue 3, 2001, Pages 215-224

  Silver, N C ^a   Good, C D ^a   Sormani, M P ^b   MacManus, D G ^a   Thompson, A J ^a   Filippi, M ^b   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Doamed imaging; Magnetic resonance imaging; Magnetic transfer; Multiple sclerosis; Triple dose gadolinium

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; APPARATUS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG TOLERABILITY; HEADACHE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; INJECTION PAIN; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION; SAMPLE; SPINAL CORD LESION; VERTIGO;

ADULT; BLOOD-BRAIN BARRIER; BRAIN; CLINICAL TRIALS; CONTRAST MEDIA; CROSS-OVER STUDIES; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SINGLE-BLIND METHOD; SPINAL CORD; STATISTICS, NONPARAMETRIC;

EID: 0035083892     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150170229     Document Type: Article

References (33)

1. Serial gadolinium enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history
2. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis
3. Major differences in the dynamics of primary and secondary progressive multiple sclerosis
4. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration
5. Relapsing-remitting multiple sclerosis: Sequential enhanced MR imaging vs clinical findings in determining disease activity
6. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis
7. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis
8. Measuring disease activity in multiple sclerosis: A correlative study of serial weekly gadolinium-enhanced MRI and immunological markers
9. Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging
10. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
11. CAMPATH-IH in multiple sclerosis
12. Cladribine in treatment of chronic progressive multiple sclerosis
13. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis
14. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
15. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: A short term study in relapsing-remitting multiple sclerosis
16. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis
17. Exploratory treatment trials in multiple sclerosis using MRI: Sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups
18. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI
19. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS
20. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging
21. Central nervous system tumor, infection, and infarction: Detection with gadolinium-enhanced magnetization transfer MR imaging
22. Sensitivity of enhanced MR in multiple sclerosis: Effects of contrast dose and magnetisation transfer contrast
23. Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis
24. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials
25. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
26. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS)
27. A reproducible repositioning method for serial magnetic resonance imaging studies of the brain in treatment trials for multiple sclerosis
28. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: Implications for clinical trials
29. MRI dynamics of brain and spinal cord in progressive multiple sclerosis
30. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing/remitting multiple sclerosis
31. Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions
32. Magnetisation transfer ratio in multiple sclerosis lesions enhancing after different doses of gadolinium
33. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology